Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is entering Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

Custirsen utilizes second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to target and inhibit production of clusterin. OncoGenex and Isis partnered in the successful discovery and initial development of custirsen. Teva and OncoGenex are responsible for the development and commercialization of custirsen, subject to their global collaboration and license agreement and subject to OncoGenex's financial obligations to Isis. Key intellectual property related to custirsen, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, the timing and costs of these activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference presentation, ... Technology Center, LLC ( ASCTC ) focused attention on an ... stem cells. His title “Asymmetric Self-Renewal by Distributed Stem ... the essence of his message to congress participants. He ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... ... addition to the traditional pin connection, Tekscan is now offering a lower-cost termination method to ... , ... 30, 2010 -- Tekscan, Inc. announces a new lower-cost connection option for its custom ...
... ... the effect of HGH on athletes and other users sports performance , ... Copenhagen, Denmark (PRWEB) June 30, 2010 -- ... improve a sportsman’s physical performance., , ,However, few researchers from Denmark revealed that the level ...
... taken the first steps toward reducing the size and ... frequency spectrum. By combining a detector and laser ... the researchers rendered unnecessary the precision alignment of optical ... detector. The new solid-state system puts to use ...
Cached Biology Technology:Lower-Cost ZIF and LIF-Compatible Connection Option for Tekscan Custom Force Sensors 2Recent Study Reports Reveals that HGH May Aid Performance 2Sandia Labs reports first monolithic terahertz solid-state transceiver 2
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... SecurePad with Fingerprint Sensor Recognized in the ... Enabling Technologies Product Category, ... SYNA ), a leading developer of human interface ... that,its SecurePad(TM) solution has been selected as a CES ...
... Cranberry sauce is not the star of the traditional ... benefits, the lowly condiment takes center stage. In fact, ... compounds in cranberries are able to alter E. coli ... illnesses (from kidney infections to gastroenteritis to tooth decay), ...
... A major study that will provide a new window ... by the La Jolla Institute for Allergy & Immunology ... five-year study, funded by the National Institute of Allergy ... of Health, could lead to revolutionary new approaches for ...
Cached Biology News:Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree 2Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree 3Cranberry sauce: good for what ails you 2Cranberry sauce: good for what ails you 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4
...
... solution has effect on enhancing an antigen-antibody ... than the one obtained by conventional methods. ... antibody used and exposure time in fluorescence/luminescence ... with high S/N ratio and low background. ...
... this enzyme exists predominantly as XDH which ... a critical plasma antioxidant. During ischemia, ... radical producing XO by oxidation of essential ... cleavage of the amino-terminus. AO has ...
... 2 bridges the gap between the 500 ... device combines the speed of the classic ... membrane area for superior recoveries from very ... of PES, Cellulose Triacetate membranes, Vivaspin 2 ...
Biology Products: